This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
All You Need to Know About ResMed (RMD) Rating Upgrade to Buy
by Zacks Equity Research
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Scoop Up These 4 GARP Stocks to Receive Handsome Returns
by Vasundhara Sawalka
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. SFM, ADBE, GE and RMD are some such stocks.
Phibro (PAHC) Up 7.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
by Zacks Equity Research
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
Here's Why ResMed (RMD) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Buy These 5 Low-Leverage Stocks to Counter Market Volatility
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt. You can buy BILI, KINS, ENGIY, ASML and RMD.
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market
by Zacks Equity Research
RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
Here's What Key Metrics Tell Us About ResMed (RMD) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0.42% and 0.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
by Zacks Equity Research
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why ResMed (RMD) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
by Urmimala Biswas
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?
by Zacks Equity Research
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
RMD Stock Benefits From the Launch of NightOwl Across US
by Zacks Equity Research
Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home.
New Product Launches Benefit GMED Stock Amid Macro Issues
by Zacks Equity Research
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare and Medtronic
by Zacks Equity Research
NVIDIA, Resmed, GE HealthCare and Medtronic are part of the Zacks top Analyst Blog.